JO3291B1 - الأجسام المضادة لـ csf-1r - Google Patents

الأجسام المضادة لـ csf-1r

Info

Publication number
JO3291B1
JO3291B1 JOP/2011/0097A JOP20110097A JO3291B1 JO 3291 B1 JO3291 B1 JO 3291B1 JO P20110097 A JOP20110097 A JO P20110097A JO 3291 B1 JO3291 B1 JO 3291B1
Authority
JO
Jordan
Prior art keywords
csf
antibodies
antibodies against
against csf
internalizing
Prior art date
Application number
JOP/2011/0097A
Other languages
English (en)
Inventor
Francoise Doody Jacqueline
Li Yanxia
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Application granted granted Critical
Publication of JO3291B1 publication Critical patent/JO3291B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يقدم الاختراع جسمًا مضادًا بشريًا يرتبط بـ CSF-1R بشري بألفة عالية. إن للأجسام المضادة وفقًا للاختراع الحالي فوائد هامة مقارنة بالأجسام المضادة المعروفة في المجال إذ أنها متعددة الوظائف وتتمثل في: تثبيط إشارات CSF-1R، امتصاص وحث انحلال CSF-1R وتحفيز ADCC في الخلية المشتملة على الأورام، الخلايا الملتهمة الكبيرة والخلايا أحادية النواة. وقد اتضح أيضًا أنها تعد فعالة في علاج اللوكيميا، سرطان الثدي وبطانة الرحم والبروستاتا وذلك بمفردها أو بالاشتراك مع دوسيتاكسيل، باكليتاكسيل، Herceptin® أو دوكسوروبيسين.
JOP/2011/0097A 2010-04-01 2011-03-22 الأجسام المضادة لـ csf-1r JO3291B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31989610P 2010-04-01 2010-04-01

Publications (1)

Publication Number Publication Date
JO3291B1 true JO3291B1 (ar) 2018-09-16

Family

ID=44010222

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0097A JO3291B1 (ar) 2010-04-01 2011-03-22 الأجسام المضادة لـ csf-1r

Country Status (30)

Country Link
US (1) US8263079B2 (ar)
EP (2) EP2552966B1 (ar)
JP (1) JP5767310B2 (ar)
KR (1) KR101439719B1 (ar)
CN (1) CN102834414B (ar)
AR (1) AR080698A1 (ar)
AU (1) AU2011232850B2 (ar)
BR (1) BR112012024564A2 (ar)
CA (1) CA2795081C (ar)
CY (1) CY1119324T1 (ar)
DK (1) DK2552966T3 (ar)
EA (1) EA021600B1 (ar)
ES (1) ES2640909T3 (ar)
HR (1) HRP20171153T1 (ar)
HU (1) HUE036379T2 (ar)
IL (1) IL222222A (ar)
JO (1) JO3291B1 (ar)
LT (1) LT2552966T (ar)
ME (1) ME02806B (ar)
MX (1) MX2012011234A (ar)
NZ (1) NZ602621A (ar)
PL (1) PL2552966T3 (ar)
PT (1) PT2552966T (ar)
RS (1) RS56219B1 (ar)
SG (1) SG183829A1 (ar)
SI (1) SI2552966T1 (ar)
TW (1) TWI402078B (ar)
UA (1) UA111818C2 (ar)
WO (1) WO2011123381A1 (ar)
ZA (1) ZA201206926B (ar)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010329934B2 (en) 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX355418B (es) 2010-05-04 2018-04-18 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
EP2812355A4 (en) * 2012-02-06 2016-03-02 Hoffmann La Roche COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EA035336B1 (ru) 2013-12-09 2020-05-29 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способ лечения связанного со старением когнитивного расстройства или заболевания
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
KR102000224B1 (ko) * 2014-02-03 2019-07-16 전대연 스마트 이메일 관리방법
KR20230086809A (ko) 2014-06-23 2023-06-15 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
BR112017008914A2 (pt) 2014-10-29 2018-01-16 Five Prime Therapeutics, Inc. método para tratar câncer, composição e uso da composição
KR20170096187A (ko) 2014-12-22 2017-08-23 파이브 프라임 테라퓨틱스, 인크. Pvns를 치료하기 위한 항-csf1r 항체
CN107709365A (zh) 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
CN113940996A (zh) 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
US20180222985A1 (en) * 2015-06-24 2018-08-09 Hoffmann-La Roche Inc. Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP3973988A1 (en) 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
WO2017085566A1 (en) * 2015-11-20 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increase/induction of immune responses
US20180291107A1 (en) * 2015-11-24 2018-10-11 Eli Lilly And Company Combination therapy for cancer
CA3005932A1 (en) * 2015-11-25 2017-06-01 Nogra Pharma Limited Il-34 antisense oligonucleotides and methods of using same
WO2017189919A2 (en) 2016-04-28 2017-11-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
TW201825519A (zh) 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
WO2018115051A1 (en) * 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018144334A1 (en) 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
UA127828C2 (uk) 2017-04-26 2024-01-17 Алкахест, Інк. Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
BR112020003533A2 (pt) 2017-08-25 2020-11-17 Five Prime Therapeutics, Inc. anticorpos b7-h4 e métodos de uso dos mesmos
BR112020004879A2 (pt) 2017-09-13 2020-09-15 Five Prime Therapeutics, Inc. métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
EP3759142A1 (en) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
BR112020018709A2 (pt) * 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
BR112020023746A2 (pt) * 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN108948200B (zh) * 2018-07-18 2019-05-10 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其应用
CN108948201B (zh) * 2018-07-18 2019-05-07 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及应用
KR20210049106A (ko) 2018-07-27 2021-05-04 알렉터 엘엘씨 항-siglec-5 항체 및 이의 사용 방법
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
CA3115308A1 (en) 2018-10-26 2020-04-30 Alkahest, Inc. Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
EP3894014A4 (en) * 2018-12-13 2022-04-20 Development Center for Biotechnology Anti-human csf-1r antibody and uses thereof
US20220137054A1 (en) * 2019-03-05 2022-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarkers and biotargets in renal cell carcinoma
WO2020232051A1 (en) * 2019-05-15 2020-11-19 Biosion Inc. Antibody binding csf-1r and use thereof
AU2020283742A1 (en) * 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
CN110499295A (zh) * 2019-09-11 2019-11-26 宝船生物医药科技(上海)有限公司 一种csf-1r报告基因细胞株及其制备方法和应用
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
WO2021076942A1 (en) * 2019-10-17 2021-04-22 National Health Research Institutes Use of succinate as biomarker in diagnosis and treatment of cancers
WO2021087105A1 (en) 2019-10-30 2021-05-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
EP4073100A4 (en) 2019-12-09 2024-02-14 Syndax Pharmaceuticals, Inc. ANTIBODIES FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
WO2024238787A1 (en) 2023-05-17 2024-11-21 Syndax Pharmaceuticals, Inc. Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
EP1572106B1 (en) * 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
MX2010001918A (es) * 2007-08-21 2010-03-11 Amgen Inc Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
CN101970496B (zh) * 2008-03-14 2014-04-16 特朗斯吉有限公司 针对csf-1r的抗体

Also Published As

Publication number Publication date
US20110243947A1 (en) 2011-10-06
SI2552966T1 (sl) 2017-08-31
JP2013529183A (ja) 2013-07-18
US8263079B2 (en) 2012-09-11
SG183829A1 (en) 2012-10-30
DK2552966T3 (en) 2017-08-14
UA111818C2 (uk) 2016-06-24
EP3156419A1 (en) 2017-04-19
BR112012024564A2 (pt) 2016-11-29
CN102834414B (zh) 2014-10-08
CA2795081C (en) 2017-12-05
HRP20171153T1 (hr) 2017-10-06
EA201270732A1 (ru) 2013-01-30
TW201138824A (en) 2011-11-16
IL222222A0 (en) 2012-12-31
EA021600B1 (ru) 2015-07-30
NZ602621A (en) 2014-02-28
WO2011123381A1 (en) 2011-10-06
PL2552966T3 (pl) 2017-12-29
ES2640909T3 (es) 2017-11-07
IL222222A (en) 2016-02-29
CN102834414A (zh) 2012-12-19
AU2011232850B2 (en) 2014-06-19
CY1119324T1 (el) 2018-02-14
EP2552966B1 (en) 2017-07-05
TWI402078B (zh) 2013-07-21
CA2795081A1 (en) 2011-10-06
JP5767310B2 (ja) 2015-08-19
PT2552966T (pt) 2017-09-29
MX2012011234A (es) 2012-11-30
ME02806B (me) 2018-01-20
AR080698A1 (es) 2012-05-02
EP2552966A1 (en) 2013-02-06
AU2011232850A1 (en) 2012-09-06
RS56219B1 (sr) 2017-11-30
LT2552966T (lt) 2017-10-10
ZA201206926B (en) 2014-03-26
KR101439719B1 (ko) 2014-09-12
HUE036379T2 (hu) 2018-07-30
KR20130001258A (ko) 2013-01-03

Similar Documents

Publication Publication Date Title
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
MY164604A (en) Anti-egfr antibodies and uses thereof
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
PH12012501720A1 (en) Therapeutic dll4 binding proteins
UA110370C2 (en) Conjugates of amatoxin with improved linkages
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
PH12012502215A1 (en) Anti-fgfr2 antibodies
PH12013502043A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
HK1255815A1 (zh) 治疗腹膜癌的组合物和方法
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2009148896A3 (en) Anti-phospho-akt antibodies
UA100694C2 (ru) АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С CD79b, ИММУНОКОНЪЮГАТ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2012028334A3 (en) Marker for sunitinib resistance formation
TN2013000387A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2